Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

eutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006, CytRx announced that arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS. The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the second half of 2007, subject to FDA clearance. Based on preliminary discussions with the FDA, CytRx is now considering a second efficacy clinical trial for ALS, possibly in parallel with the upcoming Phase IIb trial, to provide additional efficacy data to support a possible approval decision by the FDA.

The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS, which has also been granted orphan medicinal product status for the treatment of ALS by the European Commission. The Company has announced plans to commence a Phase II clinical trial for arimoclomol in stroke recovery in the first half of 2008, subject to FDA clearance. The Company has also announced plans to commence a Phase II clinical trial with its next drug candidate, iroxanadine, for diabetic foot ulcers in the first half of 2008, subject to FDA clearance. In addition, the Company plans to open a research and development facility in San Diego in the third quarter of 2007. For more information on the Company, visit www.cytrx.com.

About RXi Pharmaceuticals Corporation

Worcester, Massachusetts-based RXi Pharmaceuticals Corporation, a majority-owned subsidiary of CytRx, is a biopharmaceutical research and development company that focuses on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus is on neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi has licenses to a diverse series of early patents and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chem
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- United Medical Education, ... Life Support (ACLS), Pediatric Advanced Life Support (PALS) and ... BLS and ACLS online course manuals. In ... simply need to build an account with the company. ... these programs, United Medical Education is setting a precedent ...
(Date:5/17/2013)... BOSTON , May 17, 2013  TechAtlas ... update for their competitive landscape map for the ... highlights over 90 international companies with drugs and ... addressing CKD and its sequelae. ... include: , hypertension - renal denervation ...
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
Breaking Medicine Technology:ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3
... 11, 2011 Conatus Pharmaceuticals Inc. today announced the ... private placement financing.  This financing was led by new ... participation by existing investors; Aberdare Ventures, Advent Venture Partners, ... Fund.  Conatus will use the proceeds to advance the ...
... 2011 Stryker Corporation,s (NYSE: SYK ) ... 510(k) clearance for its MDM X3 Modular Dual Mobility ... to the company,s portfolio of next-generation technologies designed to ... and address a broader patient population, including both primary ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 3
(Date:5/18/2013)... May 18, 2013 In a May ... Preventive Double Mastectomy After Discovering Cancer Gene,” Fox News ... procedure upon learning that she carried a gene that ... breast cancer and a 50 percent risk of ovarian ... up on May 16, 2013 with a blog post ...
(Date:5/18/2013)... The Communities of Distinction TV program ... home. These are the townships, villages and other small spots ... the people are friendly and neighbors are there when you ... and shares the best in both the United States and ... sports and film celebrity. It airs in May and will ...
(Date:5/18/2013)... May 18, 2013 Family Magazine of Washington ... excellence by Follow Media Consulting, Inc. in the category of ... continued commitment and dedication of the areas best in the ... one knows parenting better than Brenda Hyde, a mother of ... help parents know about the vast resources available to them ...
(Date:5/18/2013)... The “Sleep Apnea Diagnostic & Therapeutic Devices Market ... (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, ... the major market drivers, restraints, and opportunities in North ... Browse , 147 market data ... 318 pagesand in-depth TOC of “Sleep ...
(Date:5/18/2013)... San Francisco, CA (PRWEB) May 18, 2013 ... accepting appointments for 2013 therapies. At the Ayurvedic ... the guidance of panchakarma practitioner and lifestyle ... Specialist. Ayurveda, the “knowledge of life", is the traditional ... idea that a life of harmony is the basis ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Spa Treatments Now Offered at the California College of Ayurveda Panchakarma Center 2
... Feb. 11 Abbott ( NYSE: ABT ),today ... Food and Drug,Administration (FDA) for its new, compact ... expand the company,s hematology,platform by offering a high ... laboratories. , As small ...
... Inc., a privately held company located in the Midwest, ... eliminates all of the most common problems associated with ... therapy hasn,t always been therapeutic for many people. The ... never continue therapy beyond the first night ... because ...
... Tibotec Therapeutics, a division of Centocor Ortho ... a lower-dose (75 mg) formulation of PREZISTA (darunavir) ... the FDA approval of PREZISTA, co-administered with ritonavir ... treatment of HIV infection in pediatric patients six ...
... Men, Women Differ in Oral Health Care Habits , CHICAGO, ... what do people find most attractive in others? The smile. ... Crest(R) and Oral B(R) finds that the smile outranked eyes, ... men and women differ when it comes to taking care ...
... Ongoing Study Shows Seven of 14 Evaluable Patients ... Two Treatment Cycles----Bavituximab Has Now Produced Positive Early ... Therapy Cancer Trials--TUSTIN, Calif., Feb. 11 Peregrine ... reported that its lead product candidate bavituximab achieved ...
... Sanofi-aventis announced today that Jean-Pierre ... Chief Medical Officer (CMO). He was previously Senior ... Marc Cluzel, Senior Vice President, Research & Development, who ... Officer is a further demonstration internally and externally of ...
Cached Medicine News:Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 2Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 3Health News:Husband From Small Town May Have Found Solution to Sleep Industry's 20-Year Compliance Problem 2Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 2Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 3Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 4Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 5Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 6Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 7Health News:Survey Finds Smile is 'Most Attractive' Physical Feature 2Health News:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study 2Health News:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study 3Health News:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study 4Health News:Jean-Pierre Lehner Appointed Chief Medical Officer 2
...
Solid blade speculum designed for both temporal and superior approach ocular surgery. Adjustable with thumb screw. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Adjustable lid speculum with mm blades. Miniature frame ideal for deep set eyes and small orbital structures....
Medicine Products: